Market Cap 30.37M
Revenue (ttm) 30.99M
Net Income (ttm) -141.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -456.31%
Debt to Equity Ratio -1.21
Volume 1,102,700
Avg Vol 1,936,397
Day's Range N/A - N/A
Shares Out 55.22M
Stochastic %K 91%
Beta 1.03
Analysts Sell
Price Target $1.34
G101SPM
G101SPM Jan. 9 at 8:41 PM
#SPMNOTES EXAMPLES OF G-101 SPM AI's STOCK PICKS As of January 2026, the G-101 SPM AI algorithm, co-authored by Christopher Netelkos at Northridge Company, has documented a certified history of 3,097 stock picks since its inception in March 2023. The following are documented examples of stocks selected by the algorithm and their subsequent performance: Documented Winners (Historical to 2026) According to performance audits and strategy reports published in January 2026, the AI identified several major individual winners before significant rallies: Thyssenkrupp (ETR: TKAG): Gained +223% after being selected by the AI. Super Micro Computer (NASDAQ: $SMCI): Achieved a +185.8% return while active in the AI's strategy. ABL Bio Inc (KQ: 298380): Increased by +170.30% following its selection. ViaSat Inc (NASDAQ: $VSAT): Saw a +163% rise after being picked. Colab Cloud Platforms (BO: COLA): Gained +111.80%. Banco Santander (NYSE: SAN): Achieved a +104.45% return. Nvidia (NASDAQ: $NVDA): Recorded a +226.7% gain while held within the AI strategy. Specific Case Study: Marinus Pharmaceuticals ($MRNS) A notable 2024–2025 case study from Christopher Netelkos’s "SPM Notes" highlights the algorithm's timing: The AI issued a bid at $1.50. The position was exited on January 29, 2024, at $10.26 after the "SPM tag" dropped, representing a substantial gain before the subsequent stock decline. Current Strategy Performance (January 2026) As of early January 2026, the AI's "Top Value" strategy has reportedly delivered an 83.20% return, outperforming its benchmark by 33.85%. The algorithm continues to process information from 145 unstructured data sources to identify "smart" data trends that prioritize non-human intervention over traditional conventional analytics.
0 · Reply
Godwins26
Godwins26 Nov. 13 at 8:02 PM
$NVVE and $MRNS highest gains
0 · Reply
StockStratigizer
StockStratigizer Jun. 6 at 6:50 PM
GLMD meets a lot of criteria 🔥 Biotech history shows what’s possible when the right setup meets the right spark… 📈 $RCUS$2 to $25+ on oncology momentum 📈 $CRBP$0.90 to $9+ on FDA buzz 📈 $XBIO — under $1 to $6+ on low-float madness 📈 $MRNS$1.50 to $13+ on epilepsy pipeline news ⬇️⬇️⬇️⬇️ Now look at $GLMD 🔹 Trading under $2 🔹 Book value near $12 🔹 Strong cash position 🔹 Biotech catalyst potential 🔹 Tight float 👀 Not a guarantee. Not advice. Just perspective. In biotech land, moves like these have happened before. GLMD has the ingredients. Now it’s about the catalyst.
0 · Reply
oooo_O
oooo_O May. 29 at 3:58 PM
$MRNS 🙄😉
0 · Reply
Z_Saki
Z_Saki May. 21 at 1:53 PM
$MRNS Isn't this stock delisted?
0 · Reply
MrLahey69
MrLahey69 May. 13 at 6:45 PM
$MRNS where did my shares go?
1 · Reply
bullBear1980
bullBear1980 Feb. 17 at 3:27 PM
0 · Reply
Doorkey
Doorkey Feb. 12 at 7:30 PM
$MRNS POOF!
1 · Reply
lecorb
lecorb Feb. 12 at 1:08 PM
$MRNS Suspended and delisted in Charles Schwab.
1 · Reply
Latest News on MRNS
Pacific Defense Announces US Army CMFF Program Team

Aug 13, 2024, 7:01 AM EDT - 1 year ago

Pacific Defense Announces US Army CMFF Program Team

DFTX


G101SPM
G101SPM Jan. 9 at 8:41 PM
#SPMNOTES EXAMPLES OF G-101 SPM AI's STOCK PICKS As of January 2026, the G-101 SPM AI algorithm, co-authored by Christopher Netelkos at Northridge Company, has documented a certified history of 3,097 stock picks since its inception in March 2023. The following are documented examples of stocks selected by the algorithm and their subsequent performance: Documented Winners (Historical to 2026) According to performance audits and strategy reports published in January 2026, the AI identified several major individual winners before significant rallies: Thyssenkrupp (ETR: TKAG): Gained +223% after being selected by the AI. Super Micro Computer (NASDAQ: $SMCI): Achieved a +185.8% return while active in the AI's strategy. ABL Bio Inc (KQ: 298380): Increased by +170.30% following its selection. ViaSat Inc (NASDAQ: $VSAT): Saw a +163% rise after being picked. Colab Cloud Platforms (BO: COLA): Gained +111.80%. Banco Santander (NYSE: SAN): Achieved a +104.45% return. Nvidia (NASDAQ: $NVDA): Recorded a +226.7% gain while held within the AI strategy. Specific Case Study: Marinus Pharmaceuticals ($MRNS) A notable 2024–2025 case study from Christopher Netelkos’s "SPM Notes" highlights the algorithm's timing: The AI issued a bid at $1.50. The position was exited on January 29, 2024, at $10.26 after the "SPM tag" dropped, representing a substantial gain before the subsequent stock decline. Current Strategy Performance (January 2026) As of early January 2026, the AI's "Top Value" strategy has reportedly delivered an 83.20% return, outperforming its benchmark by 33.85%. The algorithm continues to process information from 145 unstructured data sources to identify "smart" data trends that prioritize non-human intervention over traditional conventional analytics.
0 · Reply
Godwins26
Godwins26 Nov. 13 at 8:02 PM
$NVVE and $MRNS highest gains
0 · Reply
StockStratigizer
StockStratigizer Jun. 6 at 6:50 PM
GLMD meets a lot of criteria 🔥 Biotech history shows what’s possible when the right setup meets the right spark… 📈 $RCUS$2 to $25+ on oncology momentum 📈 $CRBP$0.90 to $9+ on FDA buzz 📈 $XBIO — under $1 to $6+ on low-float madness 📈 $MRNS$1.50 to $13+ on epilepsy pipeline news ⬇️⬇️⬇️⬇️ Now look at $GLMD 🔹 Trading under $2 🔹 Book value near $12 🔹 Strong cash position 🔹 Biotech catalyst potential 🔹 Tight float 👀 Not a guarantee. Not advice. Just perspective. In biotech land, moves like these have happened before. GLMD has the ingredients. Now it’s about the catalyst.
0 · Reply
oooo_O
oooo_O May. 29 at 3:58 PM
$MRNS 🙄😉
0 · Reply
Z_Saki
Z_Saki May. 21 at 1:53 PM
$MRNS Isn't this stock delisted?
0 · Reply
MrLahey69
MrLahey69 May. 13 at 6:45 PM
$MRNS where did my shares go?
1 · Reply
bullBear1980
bullBear1980 Feb. 17 at 3:27 PM
0 · Reply
Doorkey
Doorkey Feb. 12 at 7:30 PM
$MRNS POOF!
1 · Reply
lecorb
lecorb Feb. 12 at 1:08 PM
$MRNS Suspended and delisted in Charles Schwab.
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Feb. 11 at 4:15 PM
$MRNS CEO purchased 5,933 shares at $1.10 for a total of $6,526. Braunstein Scott now owns 304,600 shares. https://ceo-buys.com
2 · Reply
iiivid
iiivid Feb. 11 at 2:40 AM
$MRNS someone please teach the fucking kid to say “please”.. or cry motherfather, then I may buy 1 coin 🤣🤣🤣🤣🤣🤣🤣🤣🤣
0 · Reply
floridajoe
floridajoe Feb. 10 at 10:34 PM
$MRNS what a scam, fraud.
0 · Reply
Almora34
Almora34 Feb. 10 at 9:45 PM
$MRNS Officially end of the road...
0 · Reply
iiivid
iiivid Feb. 7 at 5:24 PM
$MRNS also Nasdaq says it is a merger, not an acquisition 🤷‍♂️🔥😊
1 · Reply
iiivid
iiivid Feb. 7 at 5:17 PM
$MRNS Nasdaq says it will be suspended, not delisted. It hopefully gets back active with a new symbol. Could be hugeeeee 🤞☀️🫶
0 · Reply
iiivid
iiivid Feb. 7 at 1:47 PM
$MRNS I will keep my shares to see what future brings, hoping MRNS to be converted to Immedica at Nasdaq with an IPO 🤷‍♂️🤞❤️
2 · Reply
Caffeine444444
Caffeine444444 Feb. 7 at 1:22 PM
$MRNS Deal was approved at .55 and will delist on February 11th
0 · Reply
iiivid
iiivid Feb. 5 at 5:15 PM
$MRNS if i am not mistaken, it is about to explode hugeeeeeeee 🤞🔥🫶
0 · Reply
iiivid
iiivid Feb. 5 at 10:44 AM
$MRNS Morgan Stanley also just bought 6%. What the fuck is happening here 🤷‍♂️🤞
0 · Reply
iiivid
iiivid Feb. 3 at 2:49 PM
$MRNS is Immedica deal off? Vanguard just bought 5% of the Company 🤷‍♂️
1 · Reply